Patients with inflammatory bowel disease and post-inflammatory polyps have an increased risk of colorectal neoplasia: A meta-analysis

INTRODUCTION

Longstanding intestinal inflammation increases the risk of colorectal neoplasia in patients with inflammatory bowel disease (IBD)[1,2]. Unlike sporadic colorectal neoplasms, IBD-related colorectal neoplasms are usually characterized by a younger onset age, more malignant behavior and a poorer prognosis[3-5]. Therefore, clinical guidelines recommend regular endoscopic surveillance for IBD patients to enable the early detection of colorectal neoplasms. Furthermore, patients with certain risk factors need to undergo an intensified surveillance strategy; these risk factors include extensive colitis, family history of colorectal cancer, concurrent primary sclerosing cholangitis or post-inflammatory polyps (PIPs)[6-9].

Post-inflammatory polyps (PIPs) are usually formed from the alternating cycling of intestinal inflammation and mucous epithelial cell regeneration. According to published data, PIPs are not rare in IBD patients, with their prevalence ranging from 4% to 74%[10,11]. To date, there is controversy in the literature regarding the necessity of a strengthened surveillance strategy for IBD patients with PIPs. Some earlier casecontrol studies showed an increased risk of colorectal neoplasia in patients with PIPs[12,13]. For this reason, clinical guidelines suggest a strengthened surveillance strategy for IBD patients with previous or present PIPs in endoscopy. However, the recommended endoscopic surveillance intervals for IBD patients with PIPs vary considerably from country to country. In addition, some recent multicenter cohort studies showed no significant correlation between PIPs and colorectal neoplasia in IBD patients, in contrast to prior views and clinical guidelines[14,15]. Unnecessary and frequent endoscopic surveillance not only decreases the quality of life of IBD patients but also increases the burdens of health care and resource stewardship. Therefore, it is crucial to explore the potential risk association between PIPs and colorectal neoplasia and to clarify the safe and reasonable endoscopic surveillance intervals for IBD patients with PIPs.

In contrast to sporadic colorectal cancer, IBD-related colorectal cancer follows a sequence of “inflammation-dysplasia-carcinoma”. In IBD patients, recurrent mucosal inflammation is the primary risk factor for intestinal neoplasia. The alternating cycling of intestinal inflammation and mucous epithelial cell regeneration provides more opportunities for transcription errors and the subsequent development of neoplasia by activating procarcinogenic genes and inhibiting tumor suppressor genes. The development of colorectal neoplasia is frequently associated with mutations,methylation and dysregulation of genes. It induces microsatellite instability, telomere shortening, and chromosomal instability and further induces tumor progression[23-26]. The related genes and molecules involve the,

MATERIALS AND METHODS

This meta-analysis was conducted and presented according to the PRISMA and MOOSE guidelines. The methods were established prior to the conduct of the review.The protocol of this study was registered in PROSPERO (CRD42020172539).

接枝率是指橡膠接枝聚合物中，接枝到橡膠粒子上的SAN樹脂質(zhì)量與橡膠質(zhì)量的比值。接枝率是衡量聚丁二烯橡膠與SAN樹脂相容性的重要指標(biāo)。接枝率可以超過(guò)100%，通常ABS接枝率在30%～60%。橡膠接枝率對(duì)最終產(chǎn)品的沖擊強(qiáng)度影響較大。

Search strategy

The following databases were searched systematically from inception up to July 31,2021: MEDLINE (PubMed), MEDLINE (Ovid), EMBASE, Cochrane Library, China National Knowledge Infrastructure (CNKI), Wan-Fang Data, China Science and Technology Journal Database (VIP) and Chinese BioMedical Literature Database(CBM). The search items included “post-inflammatory polyps”, “colorectal neoplasms”, “inflammatory bowel diseases” and their associated words. The search strategy is detailed in the Supplementary data. Additional records were identified through hand searches of reference lists in clinical guidelines and relevant articles.

Study eligibility criteria

PIPs were defined as nonneoplastic lesions originating from the mucosa after the alternating cycling of intestinal inflammation and mucous epithelial cell regeneration and were proposed to be related to excessive healing processes. PIPs are usually diagnosed by endoscopists and pathologists and have been described as inflammatory polyps, pseudopolyps or post-inflammatory polyps in the literature[10].

The following data were collected: study characteristics (first author, publication year,study design, follow-up time, study conclusions), participant characteristics (numbers of PIPs and control group, IBD phenotypes, country of origin, primary sclerosing cholangitis (PSC), family history of colon cancer, extensive colitis), andoutcome assessment (occurrence of various grades of colorectal neoplasia, including the numbers of colorectal neoplasia and its specific effective size). If the data were not reported in texts or tables, researchers contacted the corresponding author of the eligible study for additional information when necessary. Two researchers (Yehong Lv, Jun Huang) performed data extraction independently. Disagreements between individual judgments were resolved by discussion and consultation with a third researcher (Xue Huang until consensus was reached). The extracted data were listed in a homemade Excel form.

Risk of bias assessment

The methodological quality of each included study was assessed using the Risk of Bias in Nonrandomized Studies-of Interventions (ROBINS-I) assessment tool[16]. Two researchers (Yehong Lv, Jun Huang) assessed the methodological quality of each included study independently. Researchers were blinded to each other’s decisions.Disagreements between individual judgments were resolved by discussion and consultation with a third researcher (Jialing Shi) until a consensus was reached. The final score was listed in a homemade Excel form.

Outcomes of interest

The outcomes of interest were the related variables of IBD-associated colorectal neoplasia, including dysplastic number, pathologic grading, cytologic type, and time from diagnosis to dysplastic change. However, many published studies reported only 1-2 relevant indices, and most of them focused on tumor incidence. This aspect made it difficult to synthesize and analyze many other useful outcome variables for colorectal neoplasia. Because the incidence of colorectal neoplasia (including the number of cases and its effect size) well reflected the potential associations between risk factors and tumorigenesis, the researchers ultimately chose the incidence of various grades of colorectal neoplasia (including colorectal neoplasia, advanced colorectal neoplasia and colorectal cancer) as the outcome of interest in this review. Neoplasia in this review was defined as not only the malignant transformation of PIPs but also the malignant transformation of colorectal mucosa. All cases of neoplasia were diagnosed by pathological examination. Colorectal neoplasia was defined as low-grade dysplasia,high-grade dysplasia and colorectal cancer. Advanced colorectal neoplasia was defined as high-grade dysplasia and colorectal cancer. All relevant dysplasia data were extracted from final pathology reports or electronic medical records. Relevant clinical data for cases were extracted from electronic medical records.

Data extraction

The inclusion criteria were as follows: (1) Participants with confirmed IBD(including ulcerative colitis, Crohn’s disease and unclassified IBD); (2) Comparison of the colorectal neoplasia burden and prognosis between patients with PIPs and patients without PIPs; (3) Reported outcomes of interest (such as colorectal neoplasia,advanced colorectal neoplasia, colorectal cancer); and (4) Cohort study or case-control study published in English or Chinese. The exclusion criteria were as follows: (1)Participants with a known history of colorectal neoplasm before IBD diagnosis; (2)Participants with synchronous diagnoses of IBD and colorectal neoplasm; (3) Full-text versions were not available for assessing risk of bias; and (4) Reviews, case reports, or poster abstracts. Two researchers (Lv YH and Huang J) applied eligibility criteria and selected studies for inclusion in the systematic review independently. Disagreements between individual judgments were resolved by discussion and consultation with a third researcher (Jialing Shi) until a consensus was reached.

Data synthesis and analysis

Data synthesis was performed using STATA 15.0. The random-effects model was used for all data synthesis and statistical analysis. The pooled risk ratio (RR) and 95%confidence interval (95%CI:) were calculated to evaluate the potential risk between PIPs and colorectal neoplasia. When adjusted ratios were available, pooled adjusted ratios, such as the pooled adjusted hazard ratio (aHR), the pooled adjusted relative risk (aRR), or the pooled adjusted odds ratio (aOR), and their 95%CI:s were also calculated.

Researchers used thestatistic to quantify statistical heterogeneity. An2 less than 25% was considered low-level heterogeneity, 25% to 50% was considered moderatelevel heterogeneity, and more than 50% was considered high-level heterogeneity.Because the number of included studies was less than ten, funnel plots for evaluating the potential publication bias were not constructed. Instead, Begg’s test and Egger’s test were used to calculate the publication bias.

In the sensitivity analysis, the following two methods were performed to verify the robustness of the results: (1) The use of the fixed-effects model; and (2) The exclusion of outliers or studies with significant clinical heterogeneity.

For further analysis, subgroup analysis was performed according to study design(cohortcase-control study) and methodological quality (serious/criticallow/moderate/unclear risk of bias) for screening the heterogeneous origin. Because geography plays a role in IBD-associated colorectal cancer, the recommended endoscopic surveillance intervals vary considerably in different countries and societies. The geographic heterogeneity between PIPs and colorectal neoplasia was investigated in further analysis. The potential risk between PIPs and colorectal neoplasia in different IBD phenotypes (ulcerative colitis, Crohn’s disease, unclassified IBD) was also investigated in further analysis. Avalue less than 0.05 was considered significant.

Statistical analysis

The Grading of Recommendations, Assessment, Development and Evaluation(GRADE) approach was used to assess the overall quality of evidence supporting the outcomes of interest[17]. The final quality of evidence was classified as high, moderate,low or very low. The quality of evidence was assessed using GRADE profiler 3.6.

RESULTS

Study selection

Grade A (Excellent): 0

Included study characteristics

Four cohort studies and five case-control studies were included in this study. The sample sizes of participants ranged from 204 to 1582. PIPs were present in 1944/5424(35.8%) IBD patients (median prevalence, 29.7%). The median follow-up durations ranged from 3.0 to 22.9 years (median follow-up, 13.0 years). In different IBD phenotypes, five studies exclusively focused on ulcerative colitis (UC), and four remaining studies focused on mixed IBD phenotypes. In different cohort geographies,the included studies were conducted in the Netherlands (= 4), the United States of America (= 3), the United Kingdom (= 2), Belgium (= 1) and China (= 1). The summarized characteristics from the included studies are presented in Table 1.

In this study, the overall quality of evidence was assessed as moderate to low. There are several obstacles to designing and performing randomized controlled trials for endoscopic surveillance of IBD patients, such as ethical issues and the relatively low incidence of colorectal neoplasia. Thus, robust and available evidence usually comes from well-designed multicenter observational trials. Having recognized these limitations, we systematically searched several databases, undertook a meta-analysis of the latest and most favorable evidence, and used multiple methods to verify the robustness of the potential risk between PIPs and colorectal neoplasia. In the three outcomes of interest, the results did not change when researchers excluded outliers or studies with significant clinical heterogeneity. This result indicated that based on the current studies, the results of this meta-analysis are robust and that individual studies have less influence.

Risk of bias assessment

Methodological quality was assessed using the ROBINS-I. The overall bias in each included study ranged from moderate to serious. Overall, five studies had a moderate risk of bias, three studies had a serious risk of bias, and one study had an unknown risk of bias. Because of the lack of information on missing data, the study by M D Rutter had unknown risks of missing data and overall bias. The outcomes of interest in our research were not the main outcomes in some studies, which may have led to the lack of detailed data and processing methods. For this reason, studies commonly have a moderate or serious risk in the sections of “bias due to confounding”, “bias in the selection of participants for the study”, and “bias in classification of interventions”.The risk of bias assessment from each included study is presented in Table 2.

Association of PIPs with colorectal neoplasia

All nine included studies evaluated the association between PIPs and colorectal neoplasia and involved 5424 IBD patients (1944 with PIPs3480 without PIPs). A total of 553 (28.4%) IBD patients with PIPs were diagnosed with colorectal neoplasia,compared with 546 (15.7%) IBD patients without PIPs. Using a random-effects model,IBD patients with PIPs were significantly associated with a higher risk of colorectal neoplasia than IBD patients without PIPs (RR = 1.74, 95%CI: 1.35-2.24,< 0.001,=81.4%) (Figure 2A). Four studies reported the adjusted aHR ratio, three studies reported the adjusted aOR ratio, and one study reported the adjusted aRR ratio. When pooling the aHR and aOR, significant differences between these two groups were still observed (pooled aHR = 1.31, 95%CI: 1.01-1.70,= 0.04,= 26.2%; pooled aOR = 2.62,95%CI: 1.77-3.88,0.001,= 0%) (Figure 2B, 2C). Publication bias was not observed in Begg’s test or Egger’s test.

In the sensitivity analysis, IBD patients with PIPs were still significantly associated with a higher risk of colorectal neoplasia than IBD patients without PIPs when researchers used the fixed-effects model (RR = 1.67, 95%CI: 1.50-1.85,0.001,I=81.4%). The results did not change after excluding outliers or studies with significant clinical heterogeneity.

In the subgroup analysis, different study designs and methodological qualities did not change the results or heterogeneity of each group. In different IBD phenotypes,five studies exclusively focused on UC and involved 2280 patients (921 with PIPs1359 without PIPs). PIPs were also significantly associated with a higher risk of colorectal neoplasia in UC patients (RR = 1.76, 95%CI: 1.18-2.63,= 0.006,= 81.6%).Because of the lack of CD and UNCLASSIFIED IBD data, the effects of PIPs on colorectal neoplasia in CD and UNCLASSIFIED IBD patients are not available. In different cohort geographies, patients with PIPs had an increased risk of colorectal neoplasia in Europe (RR = 2.05, 95%CI: 1.62-2.59,0.001,= 60.7%) and Asia (RR =4.56, 95%CI: 1.93-10.79,0.001,not available). No association was observed in the US (RR = 1.17, 95%CI: 0.86-1.59,= 0.314,= 56.1%) (Table 3).

Association of PIPs with advanced colorectal neoplasia

Three cohort studies and three case-control studies evaluated the association between PIPs and advanced colorectal neoplasia and involved 3766 IBD patients (1264 with PIPs2502 without PIPs). A total of 339 (26.8%) IBD patients with PIPs were diagnosed with advanced colorectal neoplasia, compared with 255 (10.2%) IBD patients without PIPs. Using a random-effects model, IBD patients with PIPs were significantly associated with a higher risk of advanced colorectal neoplasia than IBD patients without PIPs (RR = 2.07, 95%CI: 1.49-2.87,0.001,= 77.4%) (Figure 3A).

Three studies reported the adjusted aHR ratio, two studies reported the adjusted aOR ratio, and one study reported the adjusted aRR ratio. When pooling the aHR,significant differences between these two groups were still observed (pooled aHR =1.63, 95%CI: 1.05-2.53,= 0.03,= 10.1%) (Figure 3B). Publication bias was notobserved in Begg’s test or Egger’s test.

In the sensitivity analysis, IBD patients with PIPs were still significantly associated with a higher risk of advanced colorectal neoplasia than IBD patients without PIPs when researchers used the fixed-effects model (RR = 1.91, 95%CI: 1.67-2.18,< 0.001,= 77.4%). The results did not change when researchers excluded outliers or studies with significant clinical heterogeneity. In the subgroup analysis, different study designs and methodological qualities did not change the results or heterogeneity of each group (Table 3).

Association of PIPs with colorectal cancer

One cohort study and three case-control studies evaluated the association between PIPs and colorectal cancer and involved 1938 IBD patients (745 with PIPs1193 without PIPs). A total of 308 (41.3%) IBD patients with PIPs were diagnosed with colorectal cancer, compared with 220 (18.4%) IBD patients without PIPs. Using a random-effects model, IBD patients with PIPs were significantly associated with a higher risk of developing colorectal cancer than IBD patients without PIPs (RR = 1.93,95%CI: 1.32-2.82,= 0.001,= 83.0%) (Figure 4). Publication bias was not observed in Begg’s test or Egger’s test. Because the adjusted ratios were not available, the pooled adjusted ratio was not calculated. Because few studies were included in this section,sensitivity analysis and subgroup analysis were not performed.

Quality of evidence

The GRADE approach was used to assess the overall quality of evidence. There is lowquality evidence to support that IBD patients with PIPs bear an increased risk of colorectal neoplasia and colorectal cancer. There is moderate-quality evidence to support that IBD patients with PIPs bear an increased risk of advanced colorectal neoplasia. A summary of the assessment is presented in Table 4.

DISCUSSION

This study aimed to explore the potential association between PIPs and colorectal neoplasia in IBD patients. The results indicated that IBD patients with PIPs bear an increased risk of colorectal neoplasia, advanced colorectal neoplasia, and colorectal cancer.

Because of the lack of large, randomized trials and meta-analyses specifically focused on the risk of PIPs and colorectal neoplasia, most of the current data are from small-scale, observational, nonrandomized studies. Therefore, researchers systematically identified and analyzed data from observed trials and evaluated the association between PIPs and colorectal neoplasia, advanced colorectal neoplasia, and colorectal cancer in IBD patients separately. This study aimed to determine whether IBD patients with PIPs bear an increased risk of various grades of colorectal neoplasia.

These changes were detectable not only in dysplastic mucosa but also in morphologically normal intestinal mucosa. Their accumulation will lead to extensive genomic and epigenomic alterations and then create a favorable microenvironment for tumor progression. This phenomenon is called field cancerization[35-37]. In theory, the earlier the field cancerization can be detected, the earlier the interventions will be to slow or stop tumor progression. Unfortunately, the above changes are invisible underendoscopy. Accurately predicting the risk of colorectal neoplasia in IBD patients in the early stage is still challenging. Therefore, looking for visible warning markers of colorectal neoplasia in IBD patients is the focus of current research.

PIPs are formed as a consequence of repeated cycles of active inflammation and regeneration of the intestinal epithelium. Under endoscopy, PIPs look like polyps or loose mucosal tags[10,38]. Although malignant transformation from PIPs is rare, IBD patients with PIPs are at an increased risk of various grades of colorectal neoplasia.Previous studies have shown that PIPs positively correlate with the severity of inflammation and are considered surrogate markers of significant cumulative inflammatory burden[26,39,40]. Given this finding, researchers have proposed that PIPs are visible markers of severe inflammation under endoscopy and an early warning of an increased risk of colorectal neoplasia in IBD patients.

In different IBD phenotypes, the colorectal neoplasia burden of UC patients with PIPs is also increased, which is consistent with the burden of IBD patients. Thus,compared with UC patients without PIPs, a strengthened surveillance strategy is preferable for UC patients with PIPs. Meanwhile, because of the lack of data on Crohn’s colitis patients, there is still doubt whether surveillance intervals should be independent of IBD phenotypes. Additional well-designed trials are needed for further research.

Geographic heterogeneity exists in the incidence of IBD and IBD-associated colorectal cancer[41-43]. Currently, there is controversy regarding reasonable endoscopic surveillance intervals for patients with PIPs. The recommended intervals vary considerably from country to country. Therefore, what actual role does geography play in PIPs and colorectal neoplasia? In this study, compared with patients without PIPs, patients with PIPs had an increased risk of colorectal neoplasia in Europe and Asia. Conversely, no association between PIPs and colorectal neoplasia has been observed in the United States. The reason for this geographic heterogeneity is multifactorial and includes genetics, diet, IBD phenotype, inflammation burden,treatment options, and differences in endoscopic surveillance. However, it is important to note that this result should be interpreted and applied cautiously because of the small numbers of included studies on certain national cohorts. More welldesigned trials are needed to verify this variation in future research. In contrast to these results, therecommends annual endoscopic surveillance for IBD patients with PIPs, which is more frequent than the every 2-3 years that is recommended by thethethe[6,8,44,45].

When an endoscopist identifies an IBD patient with concurrent PIPs, what should they do? Because IBD patients with PIPs bear an increased risk of colorectal neoplasia,it is necessary for them to enroll in a rigorous treatment program that includes strengthened endoscopic surveillance strategies to achieve complete histological mucosal healing and identify colorectal neoplasia in an early stage. The purpose of endoscopic surveillance is to detect early dysplastic changes to allow for appropriate management so that there are improvements in quality of life and survival rates. To reduce the rate of missing dysplasia, surveillance should be performed by an experienced gastroenterologist in IBD when the disease is in remission. Adequate bowel preparation, meticulous inspection with slow withdrawal, and the application of advanced endoscopic equipment are key for high-quality surveillance. Detailed recommendations of various societies for IBD patients with PIPs are summarized in Table 5.

When considering endoscopic surveillance intervals, societies recommend different intervals that range from one to three years. European societies suggest that PIPs are an intermediate risk factor for developing colorectal cancer in IBD patients and that IBD patients with PIPs should undergo endoscopic surveillance every 2-3 years[6,44,45]. Nevertheless, US and Australian societies suggest shortening the surveillance interval to every year because they believe that IBD patients with PIPs are at high risk of colorectal cancer[8,46]. In China and Japan, current guidelines and specifications do not mention a definite interval for patients with PIPs. Correspondingly, these Asian societies advocate initiating endoscopic surveillance from 8-10 years after disease onset and recommend annual or biennial endoscopic surveillance for patients with left-sided colitis or extensive colitis[47-49]. To summarize, the optimal interval of endoscopic surveillance for IBD patients with PIPs has not been established, and additional welldesigned trials are needed for further research.

How can colonoscopy screening be performed for IBD-associated colorectal cancer?During recent decades, new technology has improved in terms of endoscopic devices,including white light endoscopy (WLE), chromoendoscopy, magnifying endoscopy,endomicroscopy, narrow band imaging (NBI), and endoscopic molecular imaging.Among them, the majority of clinical guidelines recommend methylene blue or indigo carmine chromoendoscopy with targeted biopsies for surveillance colonoscopy. Under chromoendoscopy, the visualization of the colonic epithelium is improved by highlighting the areas of mucosal irregularities and delineating the borders of suspected lesions. Studies have shown that 61%-84% of neoplastic lesions could be visualized by recent endoscopy[50-53]. In this context, targeted biopsies have the advantage of fewer samples. Therefore, although chromoendoscopy takes a longer time and may be more cumbersome, chromoendoscopy with targeted biopsies has a higher dysplasia detection rate and is more cost-effective than conventional colonoscopy[54-58]. However, random biopsies are beneficial for monitoring disease progression, evaluating histologic stage and assessing treatment efficacy. In special circumstances, such as a known history of dysplasia, concomitant PSC or a foreshortened colon, random biopsies are still recommended regardless of the screening method. With advances in optical imaging techniques, it is unclear whether chromoendoscopy should still be used when surveillance is performed with highdefinition colonoscopy or new endoscopic imaging. Additional well-designed trials are needed for further research.

The increased risk of colorectal neoplasia in IBD patients with PIPs probably reflects the increased risk of previous severe inflammation rather than the PIPs themselves having malignant potential. In a multicenter cohort study, researchers found that most patients with PIPs undergo colectomy due to uncontrolled inflammation but not colorectal neoplasia[15]. Therefore, it is not necessary to remove PIPs conventionallyunless there is diagnostic uncertainty or concerning malignant features or clinical symptoms, such as bleeding or intussusception. Features of underlying malignancy include uneven redness, nodularity, villous texture, slight elevation or depression,friability, obscured vascular pattern, ulcerated or velvety surface, disruption of innominate lines, and inability to lift with submucosal injection[57,59,60]. In patients with multiple PIPs or uncontrolled inflammation, a terrible intestinal mucosal environment makes it difficult for endoscopists to identify abnormal lesions, and prophylactic colectomy should be considered[18]. To summarize, the management of IBD patients with PIPs, including prophylactic colectomy and enhanced endoscopic surveillance, requires careful consideration of the individual patient, their disease, and endoscopic and histologic factors and involves a multidisciplinary team discussion that should include gastroenterologists, surgeons and pathologists.

(2) 在運(yùn)營(yíng)線路之間應(yīng)設(shè)置聯(lián)通線，聯(lián)通線宜采用互通道岔連接接軌站。接軌站的配線應(yīng)保證進(jìn)站車輛不會(huì)因進(jìn)站進(jìn)路被占用而停在交叉口范圍內(nèi)，車站與交叉口之間的距離應(yīng)不小于1倍車輛長(zhǎng)度。

1.3.2 病害防治效果調(diào)查。每小區(qū)調(diào)查 3 個(gè)點(diǎn)， 每點(diǎn)調(diào)查40 株， 查看發(fā)病株數(shù)，求平均值。草莓移栽 50 d 后，調(diào)查根腐病發(fā)病情況，在12月查看草莓疫病發(fā)病情況。

A meta-analysis that focused on the prognostic factors for ACRN in IBD patients was published in 2021[61]. Similar to our study, the researchers found that patients with PIPs were at higher risk for ACRN based on three cohort studies and two casecontrol studies (OR = 3.29, 95%CI: 2.41-4.48,0.001,= 0%). However, this association was not confirmed in the pooled HR analysis (univariable HR = 1.67,95%CI: 0.99-2.82,= 0.05,= 0%; multivariable HR = 1.73, 95%CI: 0.88-3.40,= 0.11,= 56%). A probable reason for this result was that the number of available studies and patients included was too small for an accurate performance assessment. In contrast,we extended the search cutoff time to July 31, 2021 to include additional literature and participants. Finally, three cohort studies and three case-control studies involving 3766 IBD patients (1264 with PIPs2502 without PIPs) were included. The results showed that patients with PIPs were at higher risk for ACRN, which was confirmed in both pooled RR analysis and pooled HR analysis.

This study is the first meta-analysis to separately assess the relationship between PIP and CRN, ACRN and CRC. This study has several strengths. First, this study evaluated the association between PIPs and colorectal neoplasia, advanced colorectal neoplasia, and colorectal cancer separately. Disparity in the risk stratification of different grades of colorectal neoplasia can provide bases for surveillance strategy,treatment options and prognosis judgment. Second, this study used a new tool(ROBINS-I) to assess the methodological quality of each included study. Third, this study used multiple methods to identify the robustness of the results.

Corpus asan effective modern tool is credited for its reliability in providing concrete evidence and guide to language use.Corpus linguistics is remarkable for its capacity to display and analyze in huge amount recurring sample patterns of authentic lexical use in life(Hill,2000).

This study also has some limitations. First, the heterogeneity of outcomes is high.Therefore, researchers used multiple methods to identify the robustness of the results and conducted subgroup analyses to search for the source of heterogeneity. Second, a family history of colon cancer and concurrent primary sclerosing cholangitis have been reported as risk factors for colorectal neoplasia in several studies. However, because of missing data in the target population, no high-quality evidence could be obtained.

當(dāng)前，人類社會(huì)正全面進(jìn)入信息時(shí)代，以教育信息化帶動(dòng)教育現(xiàn)代化已成為教育創(chuàng)新與變革的重大戰(zhàn)略抉擇。教育部《教育信息化十年發(fā)展規(guī)劃（2011～2020）》指出：“實(shí)現(xiàn)教育信息化手段是要充分利用和發(fā)揮現(xiàn)代信息優(yōu)勢(shì)途徑，方法則是信息技術(shù)與教育的深度融合”“職業(yè)教育信息化是培養(yǎng)高素質(zhì)勞動(dòng)者和技能型人才的重要支撐，是教育信息化需要著重加強(qiáng)的薄弱環(huán)節(jié)”，所以，如何將現(xiàn)代信息技術(shù)更好地、更廣泛地應(yīng)用于職業(yè)教育，值得我們共同研究和探討。

CONCLUSION

IBD patients with PIPs may have an increased incidence of various grades of colorectal neoplasia. Due to the lower rate of malignant transformation, PIPs do not need to be removed conventionally. However, due to the increased risk of colorectal neoplasia,IBD patients with PIPs should undergo strengthened surveillance to detect early dysplastic changes to allow for appropriate management to improve quality of life and survival rates. Meanwhile, there are still many gaps in this field of research, such as information on safe and reasonable endoscopic surveillance intervals for patients with PIPs and the pathogenic process of PIPs in colorectal neoplasia. Therefore, additional well-designed multicenter trials are needed.

成立于1929年的中國(guó)營(yíng)造學(xué)社標(biāo)志了具有現(xiàn)代科學(xué)意義的中國(guó)自己的古代建筑史研究之發(fā)端[1]。而后1981祁英濤先生所著《怎樣鑒定古建筑》，提出了“兩查兩比五定”的古建筑鑒定原則，建構(gòu)了目前通行的我國(guó)文物建筑的年代譜系和宏觀發(fā)展規(guī)律[2]，沿用至今。但該著作也具有其局限性——忽略了地域性對(duì)鄉(xiāng)土建筑營(yíng)造方式的影響，故本文試圖以“兩查兩比五定”為行文結(jié)構(gòu)，辨析旌義坊的建造年代，探討鄉(xiāng)土建筑的斷代問(wèn)題。

Of 792 records, four cohort studies and five case-control studies involving 5424 IBD patients (1944 with PIPs3480 without PIPs) were included in this study. The overall bias in each included study ranged from moderate to serious. After meta-analyses, IBD patients with PIPs were significantly associated with a higher risk of colorectal neoplasia than IBD patients without PIPs (RR = 1.74, 95%CI: 1.35-2.24,< 0.001,=81.4%). Meanwhile, patients with PIPs also had a higher risk of advanced colorectal neoplasia (RR = 2.07, 95%CI: 1.49-2.87,< 0.001,= 77.4%) and colorectal cancer (RR= 1.93, 95%CI: 1.32-2.82,= 0.001,= 83.0%). Publication bias was not observed. And Sensitivity and subgroup analyses showed that the results are robust. The overall quality of evidence was assessed as moderate to low.

IBD patients with PIPs may have an increased incidence of various grades of colorectal neoplasia. Due to the lower rate of malignant transformation, PIPs do not need to be removed conventionally. However, due to the increased risk of colorectal neoplasia,IBD patients with PIPs should undergo strengthened surveillance to detect early dysplastic changes to allow for appropriate management to improve quality of life and survival rates.

There are still many gaps in this field of research, such as information on safe and reasonable endoscopic surveillance intervals for patients with PIPs and the pathogenic process of PIPs in colorectal neoplasia. Therefore, additional well-designed multicenter trials are needed.

The authors would like to thank Dr. Long JX from the Department of Epidemiology and Biostatistics (School of Public Health, Guangxi Medical University) for his kind help in reviewing the statistical methods and techniques mentioned in the manuscript.